home / stock / canf / canf quote
Last: | $1.97 |
---|---|
Change Percent: | -2.04% |
Open: | $2 |
Close: | $1.97 |
High: | $2.07 |
Low: | $1.96 |
Volume: | 10,456 |
Last Trade Date Time: | 04/18/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.97 | $2 | $1.97 | $2.07 | $1.96 | 10,456 | 04-18-2024 |
$1.96 | $2.095 | $1.96 | $2.11 | $1.94 | 32,005 | 04-17-2024 |
$2.08 | $2.07 | $2.08 | $2.2909 | $2.03 | 13,213 | 04-16-2024 |
$2.07 | $2.2 | $2.07 | $2.21 | $2.02 | 20,092 | 04-15-2024 |
$2.1 | $2.3155 | $2.1 | $2.34 | $2.1 | 14,349 | 04-12-2024 |
$2.28 | $2.3148 | $2.28 | $2.34 | $2.2 | 11,677 | 04-11-2024 |
$2.35 | $2.21 | $2.35 | $2.4241 | $2.21 | 11,769 | 04-10-2024 |
$2.26 | $2.38 | $2.26 | $2.498 | $2.25 | 20,912 | 04-09-2024 |
$2.4 | $2.44 | $2.4 | $2.5 | $2.29 | 9,801 | 04-08-2024 |
$2.35 | $2.35 | $2.35 | $2.57 | $2.2501 | 38,989 | 04-05-2024 |
$2.33 | $2.29 | $2.33 | $2.52 | $2.15 | 32,290 | 04-04-2024 |
$2.29 | $2.3 | $2.29 | $2.32 | $2.21 | 5,112 | 04-03-2024 |
$2.245 | $2.4 | $2.245 | $2.4 | $2.06 | 25,637 | 04-02-2024 |
$2.31 | $2.29 | $2.31 | $2.71 | $2.22 | 75,078 | 04-01-2024 |
$2.22 | $2.29 | $2.22 | $2.3 | $2.22 | 7,246 | 03-29-2024 |
$2.22 | $2.29 | $2.22 | $2.3 | $2.22 | 7,246 | 03-28-2024 |
$2.26 | $2.2333 | $2.26 | $2.26 | $2.21 | 11,264 | 03-27-2024 |
$2.18 | $2.24 | $2.18 | $2.26 | $2.18 | 8,120 | 03-26-2024 |
$2.19 | $2.23 | $2.19 | $2.24 | $2.17 | 19,009 | 03-25-2024 |
$2.23 | $2.19 | $2.23 | $2.23 | $2.12 | 17,758 | 03-22-2024 |
News, Short Squeeze, Breakout and More Instantly...
Can-Fite Biopharma Ltd Sponsored ADR Company Name:
CANF Stock Symbol:
NYSE Market:
A pivotal Phase III trial for advanced liver cancer, approved by FDA & EMA and a MASH Phase IIb are enrolling patients Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address onc...
Namodenoson demonstrated anti-fibrosis, anti-steatosis and anti-inflammatory effects in former Phase IIa study Patient enrolment for Phase IIb study is ongoing in Europe and Israel Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipelin...
Ramat Gan, Israel--(Newsfile Corp. - April 1, 2024) - Can-Fite BioPharma, Ltd. (NYSE American: CANF) announced today that it will be presenting at The 14th Annual LD Micro Invitational at the Sofitel New York on April 8th-9th, 2024. The event is expected to feature 80 companies presenting in ha...